お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、ヒトB型肝炎免疫グロブリンの世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にヒトB型肝炎免疫グロブリン市場を分類しています。
本レポートでは世界のヒトB型肝炎免疫グロブリン市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Baxter、CSL、Bayer、Grifols、Octapharma、Shanghai RAAS、、、China Biologic、Tiantan Biologic、Shuanglin Bio-pharmacy、Sichuan Yuanda Shuyang、Boya Bio-pharmaceutical、Shanghai Institute of Biological

レポートはヒトB型肝炎免疫グロブリンの主要生産者を調査し、主要地域や国の消費状況も提供します。ヒトB型肝炎免疫グロブリンの今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
    200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
    400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)

用途別の市場セグメント：
    Hepatitis B Carrier
    Hepatitis B Close Contacts

本レポートの詳細内容
本レポートは、世界のヒトB型肝炎免疫グロブリン市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてヒトB型肝炎免疫グロブリン市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）のヒトB型肝炎免疫グロブリン生産量、成長率、市場シェアを調査している。

二. 消費面では、ヒトB型肝炎免疫グロブリンの売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーのヒトB型肝炎免疫グロブリン売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のヒトB型肝炎免疫グロブリン市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本ヒトB型肝炎免疫グロブリンのレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：ヒトB型肝炎免疫グロブリンのレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： ヒトB型肝炎免疫グロブリンの世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおけるヒトB型肝炎免疫グロブリンの売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章ヒトB型肝炎免疫グロブリンメーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：ヒトB型肝炎免疫グロブリンの各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：ヒトB型肝炎免疫グロブリンの主要メーカーの概要を提供し、製品の説明と仕様、ヒトB型肝炎免疫グロブリンの売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：ヒトB型肝炎免疫グロブリンの市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

The global Human Hepatitis B Immunoglobulin market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

Human hepatitis B immunoglobulin (HBIG) is a blood-derived product that contains antibodies against the hepatitis B virus (HBV). HBIG is used for both the prevention and treatment of hepatitis B infection. Here is an overview of the prospect for human hepatitis B immunoglobulin:
1. Prevention of hepatitis B transmission: HBIG is administered to individuals at high risk of HBV transmission, such as newborns from HBV-infected mothers, healthcare workers exposed to HBV-positive blood, and individuals who have had close contact with someone infected with HBV. It provides passive immunity by rapidly increasing antibody levels against HBV, reducing the risk of infection.
2. Post-exposure prophylaxis: HBIG can be given as part of post-exposure prophylaxis, especially for individuals who have recently been exposed to HBV and have not been vaccinated or who have low or no immune response to HBV vaccines. It provides immediate protection against HBV infection while the body mounts its immune response.
3. Treatment of acute hepatitis B: HBIG can be used in the treatment of acute hepatitis B infection, especially in cases with severe symptoms or complications. It helps to reduce viral replication, control the infection, and prevent further damage to the liver. HBIG may be used in combination with antiviral medications for optimal treatment outcomes.
4. Pre-transplant and post-transplant prophylaxis: HBIG is often used in individuals undergoing liver transplantation for HBV-related liver disease. Pre-transplant HBIG administration aims to reduce viral load and prevent HBV re-infection of the transplanted liver. Post-transplant HBIG is given to suppress viral replication and provide long-term protection against HBV recurrence.
5. Long-term prophylaxis for chronic hepatitis B: In some cases of chronic hepatitis B infection, long-term HBIG administration may be recommended to maintain protective levels of antibodies and prevent disease progression or reactivation. This is often combined with antiviral medications to achieve the best outcomes.
6. Safety and efficacy: HBIG is derived from blood plasma and undergoes rigorous screening and testing to ensure safety and efficacy. However, as with any blood-derived product, there may be a minimal risk of transmitting infectious agents. The benefits of HBIG in preventing or treating HBV infection usually outweigh the potential risks.
7. Ongoing research and development: Research is ongoing to improve the efficacy, safety, and convenience of HBIG administration. This includes the development of recombinant HBIG and alternative dosing regimens to reduce the volume and frequency of administration.
Overall, the prospect for human hepatitis B immunoglobulin lies in its vital role in preventing HBV transmission, providing immediate protection after exposure, treating acute infection, and managing chronic hepatitis B. Continued research and development will further enhance the benefits and applicability of HBIG, ensuring improved outcomes for individuals at risk of or infected with HBV.
Report Covers:
This report presents an overview of global market for Human Hepatitis B Immunoglobulin, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Human Hepatitis B Immunoglobulin, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Human Hepatitis B Immunoglobulin, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Human Hepatitis B Immunoglobulin sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Human Hepatitis B Immunoglobulin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Human Hepatitis B Immunoglobulin sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Baxter, CSL, Bayer, Grifols, Octapharma, Shanghai RAAS, 、, China Biologic and Tiantan Biologic, etc.

Market Segmentation
By Company
    Baxter
    CSL
    Bayer
    Grifols
    Octapharma
    Shanghai RAAS
    、
    China Biologic
    Tiantan Biologic
    Shuanglin Bio-pharmacy
    Sichuan Yuanda Shuyang
    Boya Bio-pharmaceutical
    Shanghai Institute of Biological

Segment by Type
    100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
    200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
    400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)

Segment by Application
    Hepatitis B Carrier
    Hepatitis B Close Contacts

Segment by Region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Human Hepatitis B Immunoglobulin in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Human Hepatitis B Immunoglobulin manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Hepatitis B Immunoglobulin sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
    Table 1. Global Human Hepatitis B Immunoglobulin Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Table 2. Major Manufacturers of 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
    Table 3. Major Manufacturers of 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
    Table 4. Major Manufacturers of 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG)
    Table 5. Global Human Hepatitis B Immunoglobulin Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Table 6. Global Human Hepatitis B Immunoglobulin Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 7. Global Human Hepatitis B Immunoglobulin Revenue by Region (2019-2024) & (US$ Million)
    Table 8. Global Human Hepatitis B Immunoglobulin Revenue by Region (2025-2030) & (US$ Million)
    Table 9. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Region (2019-2024)
    Table 10. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Region (2025-2030)
    Table 11. Global Human Hepatitis B Immunoglobulin Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 12. Global Human Hepatitis B Immunoglobulin Sales by Region (2019-2024) & (K Units)
    Table 13. Global Human Hepatitis B Immunoglobulin Sales by Region (2025-2030) & (K Units)
    Table 14. Global Human Hepatitis B Immunoglobulin Sales Market Share by Region (2019-2024)
    Table 15. Global Human Hepatitis B Immunoglobulin Sales Market Share by Region (2025-2030)
    Table 16. Global Human Hepatitis B Immunoglobulin Sales by Manufacturers (2019-2024) & (K Units)
    Table 17. Global Human Hepatitis B Immunoglobulin Sales Share by Manufacturers (2019-2024)
    Table 18. Global Human Hepatitis B Immunoglobulin Revenue by Manufacturers (2019-2024) & (US$ Million)
    Table 19. Global Human Hepatitis B Immunoglobulin Revenue Share by Manufacturers (2019-2024)
    Table 20. Global Key Players of Human Hepatitis B Immunoglobulin, Industry Ranking, 2022 VS 2023 VS 2024
    Table 21. Human Hepatitis B Immunoglobulin Price by Manufacturers 2019-2024 (USD/Unit)
    Table 22. Global Human Hepatitis B Immunoglobulin Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 23. Global Human Hepatitis B Immunoglobulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Hepatitis B Immunoglobulin as of 2023)
    Table 24. Global Key Manufacturers of Human Hepatitis B Immunoglobulin, Manufacturing Base Distribution and Headquarters
    Table 25. Global Key Manufacturers of Human Hepatitis B Immunoglobulin, Product Offered and Application
    Table 26. Global Key Manufacturers of Human Hepatitis B Immunoglobulin, Date of Enter into This Industry
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Human Hepatitis B Immunoglobulin Sales by Type (2019-2024) & (K Units)
    Table 29. Global Human Hepatitis B Immunoglobulin Sales by Type (2025-2030) & (K Units)
    Table 30. Global Human Hepatitis B Immunoglobulin Sales Share by Type (2019-2024)
    Table 31. Global Human Hepatitis B Immunoglobulin Sales Share by Type (2025-2030)
    Table 32. Global Human Hepatitis B Immunoglobulin Revenue by Type (2019-2024) & (US$ Million)
    Table 33. Global Human Hepatitis B Immunoglobulin Revenue by Type (2025-2030) & (US$ Million)
    Table 34. Global Human Hepatitis B Immunoglobulin Revenue Share by Type (2019-2024)
    Table 35. Global Human Hepatitis B Immunoglobulin Revenue Share by Type (2025-2030)
    Table 36. Human Hepatitis B Immunoglobulin Price by Type (2019-2024) & (USD/Unit)
    Table 37. Global Human Hepatitis B Immunoglobulin Price Forecast by Type (2025-2030) & (USD/Unit)
    Table 38. Global Human Hepatitis B Immunoglobulin Sales by Application (2019-2024) & (K Units)
    Table 39. Global Human Hepatitis B Immunoglobulin Sales by Application (2025-2030) & (K Units)
    Table 40. Global Human Hepatitis B Immunoglobulin Sales Share by Application (2019-2024)
    Table 41. Global Human Hepatitis B Immunoglobulin Sales Share by Application (2025-2030)
    Table 42. Global Human Hepatitis B Immunoglobulin Revenue by Application (2019-2024) & (US$ Million)
    Table 43. Global Human Hepatitis B Immunoglobulin Revenue by Application (2025-2030) & (US$ Million)
    Table 44. Global Human Hepatitis B Immunoglobulin Revenue Share by Application (2019-2024)
    Table 45. Global Human Hepatitis B Immunoglobulin Revenue Share by Application (2025-2030)
    Table 46. Human Hepatitis B Immunoglobulin Price by Application (2019-2024) & (USD/Unit)
    Table 47. Global Human Hepatitis B Immunoglobulin Price Forecast by Application (2025-2030) & (USD/Unit)
    Table 48. US & Canada Human Hepatitis B Immunoglobulin Sales by Type (2019-2024) & (K Units)
    Table 49. US & Canada Human Hepatitis B Immunoglobulin Sales by Type (2025-2030) & (K Units)
    Table 50. US & Canada Human Hepatitis B Immunoglobulin Revenue by Type (2019-2024) & (US$ Million)
    Table 51. US & Canada Human Hepatitis B Immunoglobulin Revenue by Type (2025-2030) & (US$ Million)
    Table 52. US & Canada Human Hepatitis B Immunoglobulin Sales by Application (2019-2024) & (K Units)
    Table 53. US & Canada Human Hepatitis B Immunoglobulin Sales by Application (2025-2030) & (K Units)
    Table 54. US & Canada Human Hepatitis B Immunoglobulin Revenue by Application (2019-2024) & (US$ Million)
    Table 55. US & Canada Human Hepatitis B Immunoglobulin Revenue by Application (2025-2030) & (US$ Million)
    Table 56. US & Canada Human Hepatitis B Immunoglobulin Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 57. US & Canada Human Hepatitis B Immunoglobulin Revenue by Country (2019-2024) & (US$ Million)
    Table 58. US & Canada Human Hepatitis B Immunoglobulin Revenue by Country (2025-2030) & (US$ Million)
    Table 59. US & Canada Human Hepatitis B Immunoglobulin Sales by Country (2019-2024) & (K Units)
    Table 60. US & Canada Human Hepatitis B Immunoglobulin Sales by Country (2025-2030) & (K Units)
    Table 61. Europe Human Hepatitis B Immunoglobulin Sales by Type (2019-2024) & (K Units)
    Table 62. Europe Human Hepatitis B Immunoglobulin Sales by Type (2025-2030) & (K Units)
    Table 63. Europe Human Hepatitis B Immunoglobulin Revenue by Type (2019-2024) & (US$ Million)
    Table 64. Europe Human Hepatitis B Immunoglobulin Revenue by Type (2025-2030) & (US$ Million)
    Table 65. Europe Human Hepatitis B Immunoglobulin Sales by Application (2019-2024) & (K Units)
    Table 66. Europe Human Hepatitis B Immunoglobulin Sales by Application (2025-2030) & (K Units)
    Table 67. Europe Human Hepatitis B Immunoglobulin Revenue by Application (2019-2024) & (US$ Million)
    Table 68. Europe Human Hepatitis B Immunoglobulin Revenue by Application (2025-2030) & (US$ Million)
    Table 69. Europe Human Hepatitis B Immunoglobulin Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 70. Europe Human Hepatitis B Immunoglobulin Revenue by Country (2019-2024) & (US$ Million)
    Table 71. Europe Human Hepatitis B Immunoglobulin Revenue by Country (2025-2030) & (US$ Million)
    Table 72. Europe Human Hepatitis B Immunoglobulin Sales by Country (2019-2024) & (K Units)
    Table 73. Europe Human Hepatitis B Immunoglobulin Sales by Country (2025-2030) & (K Units)
    Table 74. China Human Hepatitis B Immunoglobulin Sales by Type (2019-2024) & (K Units)
    Table 75. China Human Hepatitis B Immunoglobulin Sales by Type (2025-2030) & (K Units)
    Table 76. China Human Hepatitis B Immunoglobulin Revenue by Type (2019-2024) & (US$ Million)
    Table 77. China Human Hepatitis B Immunoglobulin Revenue by Type (2025-2030) & (US$ Million)
    Table 78. China Human Hepatitis B Immunoglobulin Sales by Application (2019-2024) & (K Units)
    Table 79. China Human Hepatitis B Immunoglobulin Sales by Application (2025-2030) & (K Units)
    Table 80. China Human Hepatitis B Immunoglobulin Revenue by Application (2019-2024) & (US$ Million)
    Table 81. China Human Hepatitis B Immunoglobulin Revenue by Application (2025-2030) & (US$ Million)
    Table 82. Asia Human Hepatitis B Immunoglobulin Sales by Type (2019-2024) & (K Units)
    Table 83. Asia Human Hepatitis B Immunoglobulin Sales by Type (2025-2030) & (K Units)
    Table 84. Asia Human Hepatitis B Immunoglobulin Revenue by Type (2019-2024) & (US$ Million)
    Table 85. Asia Human Hepatitis B Immunoglobulin Revenue by Type (2025-2030) & (US$ Million)
    Table 86. Asia Human Hepatitis B Immunoglobulin Sales by Application (2019-2024) & (K Units)
    Table 87. Asia Human Hepatitis B Immunoglobulin Sales by Application (2025-2030) & (K Units)
    Table 88. Asia Human Hepatitis B Immunoglobulin Revenue by Application (2019-2024) & (US$ Million)
    Table 89. Asia Human Hepatitis B Immunoglobulin Revenue by Application (2025-2030) & (US$ Million)
    Table 90. Asia Human Hepatitis B Immunoglobulin Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 91. Asia Human Hepatitis B Immunoglobulin Revenue by Region (2019-2024) & (US$ Million)
    Table 92. Asia Human Hepatitis B Immunoglobulin Revenue by Region (2025-2030) & (US$ Million)
    Table 93. Asia Human Hepatitis B Immunoglobulin Sales by Region (2019-2024) & (K Units)
    Table 94. Asia Human Hepatitis B Immunoglobulin Sales by Region (2025-2030) & (K Units)
    Table 95. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales by Type (2019-2024) & (K Units)
    Table 96. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales by Type (2025-2030) & (K Units)
    Table 97. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue by Type (2019-2024) & (US$ Million)
    Table 98. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue by Type (2025-2030) & (US$ Million)
    Table 99. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales by Application (2019-2024) & (K Units)
    Table 100. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales by Application (2025-2030) & (K Units)
    Table 101. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue by Application (2019-2024) & (US$ Million)
    Table 102. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue by Application (2025-2030) & (US$ Million)
    Table 103. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 104. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue by Country (2019-2024) & (US$ Million)
    Table 105. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue by Country (2025-2030) & (US$ Million)
    Table 106. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales by Country (2019-2024) & (K Units)
    Table 107. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales by Country (2025-2030) & (K Units)
    Table 108. Baxter Company Information
    Table 109. Baxter Description and Major Businesses
    Table 110. Baxter Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 111. Baxter Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 112. Baxter Recent Developments
    Table 113. CSL Company Information
    Table 114. CSL Description and Major Businesses
    Table 115. CSL Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 116. CSL Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 117. CSL Recent Developments
    Table 118. Bayer Company Information
    Table 119. Bayer Description and Major Businesses
    Table 120. Bayer Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 121. Bayer Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 122. Bayer Recent Developments
    Table 123. Grifols Company Information
    Table 124. Grifols Description and Major Businesses
    Table 125. Grifols Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 126. Grifols Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 127. Grifols Recent Developments
    Table 128. Octapharma Company Information
    Table 129. Octapharma Description and Major Businesses
    Table 130. Octapharma Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 131. Octapharma Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 132. Octapharma Recent Developments
    Table 133. Shanghai RAAS Company Information
    Table 134. Shanghai RAAS Description and Major Businesses
    Table 135. Shanghai RAAS Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 136. Shanghai RAAS Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 137. Shanghai RAAS Recent Developments
    Table 138. 、 Company Information
    Table 139. 、 Description and Major Businesses
    Table 140. 、 Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 141. 、 Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 142. 、 Recent Developments
    Table 143. China Biologic Company Information
    Table 144. China Biologic Description and Major Businesses
    Table 145. China Biologic Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 146. China Biologic Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 147. China Biologic Recent Developments
    Table 148. Tiantan Biologic Company Information
    Table 149. Tiantan Biologic Description and Major Businesses
    Table 150. Tiantan Biologic Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 151. Tiantan Biologic Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 152. Tiantan Biologic Recent Developments
    Table 153. Shuanglin Bio-pharmacy Company Information
    Table 154. Shuanglin Bio-pharmacy Description and Major Businesses
    Table 155. Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 156. Shuanglin Bio-pharmacy Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 157. Shuanglin Bio-pharmacy Recent Developments
    Table 158. Sichuan Yuanda Shuyang Company Information
    Table 159. Sichuan Yuanda Shuyang Description and Major Businesses
    Table 160. Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 161. Sichuan Yuanda Shuyang Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 162. Sichuan Yuanda Shuyang Recent Developments
    Table 163. Boya Bio-pharmaceutical Company Information
    Table 164. Boya Bio-pharmaceutical Description and Major Businesses
    Table 165. Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 166. Boya Bio-pharmaceutical Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 167. Boya Bio-pharmaceutical Recent Developments
    Table 168. Shanghai Institute of Biological Company Information
    Table 169. Shanghai Institute of Biological Description and Major Businesses
    Table 170. Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 171. Shanghai Institute of Biological Human Hepatitis B Immunoglobulin Product Model Numbers, Pictures, Descriptions and Specifications
    Table 172. Shanghai Institute of Biological Recent Developments
    Table 173. Key Raw Materials Lists
    Table 174. Raw Materials Key Suppliers Lists
    Table 175. Human Hepatitis B Immunoglobulin Distributors List
    Table 176. Human Hepatitis B Immunoglobulin Customers List
    Table 177. Human Hepatitis B Immunoglobulin Market Trends
    Table 178. Human Hepatitis B Immunoglobulin Market Drivers
    Table 179. Human Hepatitis B Immunoglobulin Market Challenges
    Table 180. Human Hepatitis B Immunoglobulin Market Restraints
    Table 181. Research Programs/Design for This Report
    Table 182. Key Data Information from Secondary Sources
    Table 183. Key Data Information from Primary Sources
List of Figures
    Figure 1. Human Hepatitis B Immunoglobulin Product Picture
    Figure 2. Global Human Hepatitis B Immunoglobulin Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Human Hepatitis B Immunoglobulin Market Share by Type in 2023 & 2030
    Figure 4. 100IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Product Picture
    Figure 5. 200IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Product Picture
    Figure 6. 400IU/Bottle Human Hepatitis B Immunoglobulin (HBIG) Product Picture
    Figure 7. Global Human Hepatitis B Immunoglobulin Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 8. Global Human Hepatitis B Immunoglobulin Market Share by Application in 2023 & 2030
    Figure 9. Hepatitis B Carrier
    Figure 10. Hepatitis B Close Contacts
    Figure 11. Human Hepatitis B Immunoglobulin Report Years Considered
    Figure 12. Global Human Hepatitis B Immunoglobulin Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Human Hepatitis B Immunoglobulin Revenue 2019-2030 (US$ Million)
    Figure 14. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Region in Percentage: 2023 Versus 2030
    Figure 15. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Region (2019-2030)
    Figure 16. Global Human Hepatitis B Immunoglobulin Sales 2019-2030 ((K Units)
    Figure 17. Global Human Hepatitis B Immunoglobulin Sales Market Share by Region (2019-2030)
    Figure 18. US & Canada Human Hepatitis B Immunoglobulin Sales YoY (2019-2030) & (K Units)
    Figure 19. US & Canada Human Hepatitis B Immunoglobulin Revenue YoY (2019-2030) & (US$ Million)
    Figure 20. Europe Human Hepatitis B Immunoglobulin Sales YoY (2019-2030) & (K Units)
    Figure 21. Europe Human Hepatitis B Immunoglobulin Revenue YoY (2019-2030) & (US$ Million)
    Figure 22. China Human Hepatitis B Immunoglobulin Sales YoY (2019-2030) & (K Units)
    Figure 23. China Human Hepatitis B Immunoglobulin Revenue YoY (2019-2030) & (US$ Million)
    Figure 24. Asia (excluding China) Human Hepatitis B Immunoglobulin Sales YoY (2019-2030) & (K Units)
    Figure 25. Asia (excluding China) Human Hepatitis B Immunoglobulin Revenue YoY (2019-2030) & (US$ Million)
    Figure 26. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales YoY (2019-2030) & (K Units)
    Figure 27. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue YoY (2019-2030) & (US$ Million)
    Figure 28. The Human Hepatitis B Immunoglobulin Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
    Figure 29. The Top 5 and 10 Largest Manufacturers of Human Hepatitis B Immunoglobulin in the World: Market Share by Human Hepatitis B Immunoglobulin Revenue in 2023
    Figure 30. Global Human Hepatitis B Immunoglobulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 31. Global Human Hepatitis B Immunoglobulin Sales Market Share by Type (2019-2030)
    Figure 32. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2019-2030)
    Figure 33. Global Human Hepatitis B Immunoglobulin Sales Market Share by Application (2019-2030)
    Figure 34. Global Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2019-2030)
    Figure 35. US & Canada Human Hepatitis B Immunoglobulin Sales Market Share by Type (2019-2030)
    Figure 36. US & Canada Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2019-2030)
    Figure 37. US & Canada Human Hepatitis B Immunoglobulin Sales Market Share by Application (2019-2030)
    Figure 38. US & Canada Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2019-2030)
    Figure 39. US & Canada Human Hepatitis B Immunoglobulin Revenue Share by Country (2019-2030)
    Figure 40. US & Canada Human Hepatitis B Immunoglobulin Sales Share by Country (2019-2030)
    Figure 41. U.S. Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 42. Canada Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 43. Europe Human Hepatitis B Immunoglobulin Sales Market Share by Type (2019-2030)
    Figure 44. Europe Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2019-2030)
    Figure 45. Europe Human Hepatitis B Immunoglobulin Sales Market Share by Application (2019-2030)
    Figure 46. Europe Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2019-2030)
    Figure 47. Europe Human Hepatitis B Immunoglobulin Revenue Share by Country (2019-2030)
    Figure 48. Europe Human Hepatitis B Immunoglobulin Sales Share by Country (2019-2030)
    Figure 49. Germany Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 50. France Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 51. U.K. Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 52. Italy Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 53. Russia Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 54. China Human Hepatitis B Immunoglobulin Sales Market Share by Type (2019-2030)
    Figure 55. China Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2019-2030)
    Figure 56. China Human Hepatitis B Immunoglobulin Sales Market Share by Application (2019-2030)
    Figure 57. China Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2019-2030)
    Figure 58. Asia Human Hepatitis B Immunoglobulin Sales Market Share by Type (2019-2030)
    Figure 59. Asia Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2019-2030)
    Figure 60. Asia Human Hepatitis B Immunoglobulin Sales Market Share by Application (2019-2030)
    Figure 61. Asia Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2019-2030)
    Figure 62. Asia Human Hepatitis B Immunoglobulin Revenue Share by Region (2019-2030)
    Figure 63. Asia Human Hepatitis B Immunoglobulin Sales Share by Region (2019-2030)
    Figure 64. Japan Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 65. South Korea Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 66. China Taiwan Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 67. Southeast Asia Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 68. India Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 69. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales Market Share by Type (2019-2030)
    Figure 70. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue Market Share by Type (2019-2030)
    Figure 71. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales Market Share by Application (2019-2030)
    Figure 72. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue Market Share by Application (2019-2030)
    Figure 73. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Revenue Share by Country (2019-2030)
    Figure 74. Middle East, Africa and Latin America Human Hepatitis B Immunoglobulin Sales Share by Country (2019-2030)
    Figure 75. Brazil Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 76. Mexico Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 77. Turkey Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 78. Israel Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 79. GCC Countries Human Hepatitis B Immunoglobulin Revenue (2019-2030) & (US$ Million)
    Figure 80. Human Hepatitis B Immunoglobulin Value Chain
    Figure 81. Human Hepatitis B Immunoglobulin Production Process
    Figure 82. Channels of Distribution
    Figure 83. Distributors Profiles
    Figure 84. Bottom-up and Top-down Approaches for This Report
    Figure 85. Data Triangulation
    Figure 86. Key Executives Interviewed